Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Contemp Clin Trials. 2015 Jan 29;41:172–179. doi: 10.1016/j.cct.2015.01.016

Table 1.

Available treatment regimens for a study of a long-peptide vaccine (LPV7) plus TLR agonists for resected stage IIB–IV melanoma.

Zone Regimen Peptide Vaccine Adjuvant Preparation Dose of TLR agonists
Z 1 d 1 LPV7 + tet IFA —
Z 1 d 2 LPV7 + tet PolyICLC 1 mg
Z 1 d 3 LPV7 + tet Resquimod 112.5 mcg
Z 2 d 4 LPV7 + tet IFA + PolyICLC 1 mg / 112.5 mcg
Z 2 d 5 LPV7 + tet IFA + Resquimod 1 mg
Z 2 d 6 LPV7 + tet PolyICLC + Resquimod 112.5 mcg
Z 3 d 7 LPV7 + tet IFA + PolyICLC + Resquimod 1 mg / 112.5 mcg